# KLOW Dosing Context — Research-only doses and routes for each component > Documentation of the doses and routes used in published KLOW-component research. Research-context only. No human-use instruction. The four-peptide blend has no standardized research dose. Each KLOW component has its own monotherapy dose record. The blend has no peer-reviewed combination dose. This sheet documents what was studied, not what to administer. ## Framing note This sheet documents the doses and routes that appear in the published literature for each of the four KLOW components separately. It is a reference inventory, not a protocol. No validated human dose exists for the four-peptide blend: the blend has no peer-reviewed pharmacokinetic study, and the component-level doses — measured in micrograms per kilogram in rodents, nanomolar concentrations in cell culture, and percentage formulations in topical human work — do not add up into a single KLOW dose. The pharmacokinetic mismatch built into the vial is also documented here: BPC-157's elimination half-life runs under thirty minutes in the formal study, the two tripeptides (KPV, GHK-Cu) clear faster still, and the TB-500 fragment differs from native thymosin beta-4 whose half-life is dose-proportional. One co-formulated dose cannot hold all four at matched exposures. This sheet reports those facts. It does not recommend any dose for any species. ## Framing — research context, not instruction Every dose documented on this sheet appears as it was published in the peer-reviewed literature. KLOW Meds does not recommend doses, does not direct administration, and does not address human use. The blend is a research-only formulation; none of its four components holds FDA approval for any indication. The blend itself has no standardized human research dose. KLOW is most commonly supplied as an 80 mg lyophilized vial containing GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg, reconstituted with bacteriostatic water by the end researcher [composition documented in supplier listings; combination not characterized in peer-reviewed pharmacokinetic literature]. ## Per-component research-context doses **BPC-157.** The dominant rodent musculoskeletal dose is 10 micrograms per kilogram intraperitoneal once daily [1,4,23]. Lower doses of 10 nanograms per kilogram and 10 picograms per kilogram have also been studied in tendon healing and have shown measurable effects [4]. Per-oral exposure in drinking water at the equivalent total daily mass has been studied in myotendinous junction recovery [23] and in brain-gut axis models [17]. In cell culture, BPC-157 acts in the nanomolar range, as documented in the VEGFR2 internalization study [2] and the Src-Caveolin-1-eNOS vasomotor work where concentrations from 10 nanomolar to 1 micromolar were tested in tissue bath [3]. The single Phase II human trial used a PL 14736 rectal enema; the specific dose was not reported in the published abstract [5]. **GHK-Cu.** Topical formulations used in human-skin studies are typically 0.01-0.05% by mass [6]. In cell culture, GHK-Cu acts in the nanomolar-to-micromolar range, including in the Connectivity Map gene-expression work [8] and the hair follicle organ-culture studies [9]. Research administration routes have included topical, intradermal, and subcutaneous. **TB-500 / thymosin beta-4.** In dermal trials, topical formulations of 0.01-0.03% were used in patients with stasis and pressure ulcers [10]. The Phase 3 ophthalmic formulation is 0.1% solution (RGN-259) [13]. In Phase 1 systemic safety work, single intravenous doses ranged from 42 mg to 1260 mg in healthy volunteers, with multiple-dose 14-day regimens also studied [12]. The 2025 cardiac trial used 0.5 microgram per kilogram and 1.0 microgram per kilogram intravenously, within 12 hours of PCI and on days 2-7 [18]. **KPV.** The canonical murine colitis dose is 100 micromolar in drinking water (oral) [14]; the same route was used in the colitis-associated cancer follow-up [15]. In cell culture, KPV is studied in the micromolar range [16]. No human-use dose has been published. ## Half-lives and pharmacokinetic notes Plasma kinetics differ across the four components. BPC-157 plasma half-life is reported as under 30 minutes in rat and dog studies, with rapid tissue distribution; one observation that has shaped how the compound is framed in research is its apparent ability to act per-oral despite the short plasma window. GHK-Cu has rapid plasma clearance; copper-bound forms penetrate skin and are typically formulated topically. Thymosin beta-4 has a multi-hour systemic half-life in humans, as characterized in the Phase 1 IV pharmacokinetic work [12]. KPV has a very short plasma half-life as a tripeptide but accumulates at PepT1-expressing inflamed tissue, partly compensating for short systemic exposure [14]. No published pharmacokinetic profile exists for the four peptides co-administered in a fixed-ratio blend. Pharmacokinetic interactions, the plasma stability of co-blended peptides, and tissue distribution under combination dosing remain uncharacterized. ## Routes studied per component (research record) Across the published literature, the routes that have been studied for each KLOW component are: intraperitoneal (rodent preclinical, all four components in monotherapy); subcutaneous (rodent preclinical); topical (GHK-Cu and TB-500 in human dermal and ophthalmic trials; KPV in animal dermal models); oral / per-oral (BPC-157 and KPV both demonstrate oral activity in rodent studies [14,17]); and intravenous (TB-500 / thymosin beta-4 in human Phase 1 and Phase 2/3 cardiac trials [12,18]). The blend's combination route has not been characterized in any peer-reviewed study. ## Storage and stability — research handling notes Lyophilized peptide blends require cold-chain storage prior to reconstitution per supplier protocols. Reconstituted peptide solutions are typically used within 28 days when stored at 2-8 C with bacteriostatic water in research settings. Bacteriostatic water is sterile water containing 0.9% benzyl alcohol as a preservative — the standard reconstitution solvent for research peptides. Sterility, endotoxin, and purity standards vary widely across research-chemical suppliers. The researcher is responsible for verifying certificate-of-analysis data before any laboratory work. --- A technical reference set for the peer-reviewed literature — not a clinic, not a vendor, not a prescription.